Angiotensin inhibition and malignancies: a review.

J Hum Hypertens

Department of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Published: October 2009

After an early report that patients treated with angiotensin-converting enzyme (ACE) inhibitors had a lower than expected incidence of cancers, there was a large number of publications investigating the possible pathophysiological mechanism mediating this effect, as well as population studies comparing the incidence of cancers in patients treated with agents inhibiting the renin-angiotensin system with their incidence in the general population. Several mechanisms are proposed to explain a potential anti-tumour activity of such agents in vitro in experimental animal models. However, the population studies are mostly inconclusive, although they do suggest a possible interaction between ACE genotypes and susceptibility to altered behaviour of certain tumours.

Download full-text PDF

Source
http://dx.doi.org/10.1038/jhh.2009.21DOI Listing

Publication Analysis

Top Keywords

patients treated
8
incidence cancers
8
population studies
8
angiotensin inhibition
4
inhibition malignancies
4
malignancies review
4
review early
4
early report
4
report patients
4
treated angiotensin-converting
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!